Comparative Pharmacology
Head-to-head clinical analysis: FLUOXYMESTERONE versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXYMESTERONE versus VIRILON.
FLUOXYMESTERONE vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."